Dec 22024 New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia FELIX study results reveal obe-cel’s potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.
